Sign in

NCT05295407Recruiting

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)

Source: ClinicalTrials.gov · Last updated 27 Feb 2026

Brief summary (registry, in English)

Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
13 Dec 2021
Start date
13 Dec 2021
Primary completion date
13 Dec 2026
Lead sponsor
Endeavor Health
NCT number
NCT05295407

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 13 Dec 2021 to the primary completion date, 13 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous diagnosis of prostate cancer.
  • Any prior PSA test result outside the range of inclusion criterion.

Other

  • Ethnicity outside the inclusion criterion (including mixed ethnicity).

Who the study is looking for

  • Consecutive patients undergoing prostate biopsy for detection of prostate cancer
  • Aged 40 to 69 years
  • Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
  • PSA between 2.5-10 ng/mL

Age in the registry: 40 years to 69 years · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
NorthShore University HealthSystem
Coordinator of this site? Confirm its status		EvanstonUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.